Shenzhen Luwei Biotechnology (Biomanifold Technology) Co., Limited, of which the technology team has a total of more than 30 years industrial experience in highly successful IVD companies in the United States; of which the operation team comes from the founder of a local public company and strives to the second entrepreneurship adventure, is committed to the research and development of molecular diagnostic clinical applications suitable for the Chinese heritage and other heritages, covering cancer and other severe diseases. The technology anchor point is the pioneering algorithm models with genomic transcriptome, which provides clinically actionable multi-gene diagnosis products for doctors and patients, including cancer recurrence, disease-free survival, overall survival, treatment response, early diagnosis, and prognosis evaluation, to ensure doctors and patients make data-driven precise medication decisions as to postoperative chemotherapy, treatment optimization, drug effect evaluation, disease surveillance and so on. Biomanifold Technology is committed to providing IVD products and third-party clinical laboratory services for clinicians, patients and pharmaceutical companies, so as to make due contributions to promoting the advanced precision medicine in China and across the globe.